

hTERT((611-626) Circular RNA for Cancer Vaccine Research

Catalog Number:CVAC-ORNA-0459

DESCRIPTION	
Product Name	hTERT((611-626) Circular RNA for Cancer Vaccine Research
Gene Name	hTERT((611-626)
Source	In vitro transcribed mRNA was further circularized to make this product as a circular RNA.
Alternative names	Telomerase Peptide Vaccine GV1001
SPECIFICATIONS	
Cap	
5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF	hTERT((611-626)
3'-UTR	3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail	
Modifications	N1-methyl-pseudouridine
Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol	Cholesterol
Ionizable Lipid	1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid	Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)
Storage	-80 °C
Buffer	PBS, pH7.5
Cryoprotectant	Trehalose
BACKGROUND	
Gene Accession	
Gene Alias	Telomerase Peptide Vaccine GV1001

(CTL) response against telomerase-expressing cells. (NCIT_C62756).

Background

Description: A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with the telomerase peptide GV1001 may activate the immune system to mount a cytotoxic T-lymphocyte